Introduction: At the time of writing the US stock market is set for its 70th record close of the year. Older market watchers will know that a wall of worry is what
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 via Vox Markets
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 via Vox Markets
Introduction: At the time of writing the US stock market is set for its 70th record close of the year. Older market watchers will know that a wall of worry is what
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 Countdown – 4 to 1 (Part 4) via Vox Markets
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have in
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 Countdown – 9 to 5 (Part 3) via Vox Markets
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have in
Traders Cafe with Zak Mir: The Top 20 Stocks For 2022 Countdown – 14 to 10 (Part 2) via Vox Markets
The Top 20 For 2022: Of course, at this time of the year, everyone and their mother deliver their list for the winners of the New Year, as I have
OKYO Pharma Limited (OKYO.L) IND filing Q3 2022 and Phase 2 initiation Q4 2022
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
OKYO Pharma Limited (OKYO.L) Publication of a Prospectus
Prospectus Publication Announcement
OKYO Pharma Limited (OKYO.L) Positive Data in an Animal Model using OK-201
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
OKYO Pharma Limited (OKYO.L) Appointment of Chief Scientific Officer
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
